Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2022-12-21 Regulatory Filings
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release dated December 21, 2022, announcing a commercial partnership between THERACLION and the University of Virginia (UVA) Cancer Center for a pilot study on breast cancer treatment using HIFU technology. It details the study protocol, the scientific rationale, and includes quotes from a UVA physician. This type of announcement, focusing on a specific business development, partnership, or clinical trial update, does not fit neatly into the core financial reporting categories (10-K, IR, ER, MRQ). It is a general corporate announcement regarding business operations and clinical progress. Since it is not a formal regulatory filing like a Director's Dealing (DIRS) or a Major Shareholding Notification (MRQ), and it is not a transcript (CT) or a formal presentation (IP), the most appropriate category is the general 'Regulatory Filings' fallback, as press releases often serve as the primary means of disseminating non-mandatory, yet material, information to the market, especially in European contexts where RNS is common for such news. Given the content is a news announcement about a partnership and clinical trial, RNS (Regulatory Filings) is the best fit among the provided options for a general corporate update that isn't a specific financial report or management change.
2022-12-21 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated November 14th, 2022, detailing the company's (THERACLION) participation and presentation of clinical advances at an international symposium (8th International Symposium on Focused Ultrasound). It discusses clinical results for their SONOVEIN® and Echopulse® technologies in treating varicose veins, thyroid nodules, and breast cancer. This content is typical of an announcement intended for investors and the public regarding scientific/clinical progress, rather than a formal regulatory filing (like 10-K, IR, or ER). Since it is an announcement about clinical progress and scientific engagement, it does not fit neatly into the specific categories like Earnings Release (ER), Interim Report (IR), or Audit Report (AR). It is best classified as a general announcement or news item. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, informational corporate announcements that don't fit elsewhere, although 'Investor Presentation' (IP) might seem close, this is a press release *about* presentations, not the presentation itself. Given the nature of sharing clinical updates outside of mandatory financial reporting, RNS is the most appropriate fallback.
2022-11-14 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release dated November 14, 2022, detailing clinical advancements presented by Theraclion at the 8th International Focused Ultrasound Symposium. It discusses results for their SONOVEIN® (varicose veins) and Echopulse® (thyroid nodules) technologies, and ongoing studies for breast cancer treatment. This content—a summary of scientific/clinical presentations and company updates outside of mandatory periodic financial filings (like 10-K or IR)—is characteristic of an Investor Presentation (IP) or a general corporate update. Since it focuses heavily on presenting clinical data and technology progress to the scientific and investment community, 'Investor Presentation' (IP) is the most fitting category, even though it is formatted as a press release announcing participation in a symposium. It is not a formal regulatory filing, earnings release, or management discussion.
2022-11-14 French
Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise à disposition du rapport financier semestriel
Report Publication Announcement Classification · 98% confidence The document is a short press release dated November 1, 2022, announcing that Theraclion has made its 'rapport financier semestriel 2022' (half-year financial report for 2022) available to the public on its website. The text explicitly states the report 'a été mis à disposition du public' (has been made available to the public) and provides a link. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). The content is not the comprehensive report itself (which would be an Interim/Quarterly Report, IR), but rather the announcement of its availability.
2022-11-01 French
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release dated October 31, 2022, announcing the departure of the Chief Executive Officer (Monsieur David Caumartin) and outlining the interim management structure (Monsieur David Auregan taking over as interim CEO). This content directly relates to changes in senior management personnel. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category.
2022-10-31 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated October 17, 2022, announcing a clinical milestone (last patient treated in a US study for SONOVEIN®) and presenting early results at the AVLS congress. It details clinical outcomes, quotes management and investigators, and outlines next steps (pivotal study). This content structure—a news announcement about operational/clinical progress rather than a formal financial filing (like 10-K, IR, or ER)—is characteristic of a general corporate announcement. Since there is no specific category for clinical trial updates or press releases about operational milestones, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory or corporate news that doesn't fit the specific financial/governance codes.
2022-10-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.